Semax: The Research Peptide Overview for Laboratory Use

Semax is a synthetic heptapeptide — the ACTH(4-7) fragment Met-Glu-His-Phe joined to a Pro-Gly-Pro tail — developed in Russia as a metabolically stabilized, non-corticotropic melanocortin analog. Research examines its effects on neurotrophin expression, cerebral ischemia models, learning and memory tasks, and stress physiology. It is supplied for laboratory research use only.

What Semax Is and Where It Came From

Semax belongs to a family of short peptides derived from adrenocorticotropic hormone (ACTH). The parent molecule, ACTH, is a 39-amino-acid pituitary hormone, but decades of fragment work established that its behavioral and neurotrophic activities could be separated from its steroidogenic activity. The ACTH(4-10) region carried much of the neurotropic signal without driving cortisol release; ACTH(4-7) — Met-Glu-His-Phe — retained activity in a still shorter form.

The practical problem with such a fragment is survival time. Free tetrapeptides are cleaved rapidly by aminopeptidases and carboxypeptidases in plasma and tissue. Researchers at the Institute of Molecular Genetics and Moscow State University addressed this by appending the tripeptide Pro-Gly-Pro to the C-terminus. That proline-flanked tail sharply slows exopeptidase attack and, notably, is itself a biologically active peptide studied independently in the same literature. The resulting sequence — Met-Glu-His-Phe-Pro-Gly-Pro — is what the field calls Semax.

Because the melanocortin core is preserved but the corticotropic portion is not, Semax is repeatedly described in published work as non-hormonal in the endocrine sense: it does not act as an ACTH receptor agonist driving adrenal steroid output in the way the full hormone does. That distinction is central to how the compound is framed in research settings.

Semax, Semax amidate, and adamantyl variants

Several structural relatives circulate in research supply. The amidated form replaces the free C-terminal carboxyl group with a carboxamide, a common medicinal-chemistry modification intended to further resist carboxypeptidase cleavage and alter charge at physiological pH. N-adamantyl Semax (commonly sold as Adamax) attaches a bulky lipophilic adamantane cage, a modification generally explored for altered membrane interaction and duration. These are distinct chemical entities with distinct analytical signatures — a point that matters when reading a COA — and Real Peptides maintains separate comparison guides covering how each variant differs from base Semax.

Reported Mechanism of Action

No single receptor fully explains the profile reported for Semax, and honest summaries of the literature say so. What the published work describes is a convergence of several plausible mechanisms.

Neurotrophin induction

The most consistently reported mechanism is upregulation of neurotrophic factor signaling. Work published in Cellular and Molecular Neurobiology reported that Semax and Pro-Gly-Pro activate transcription of neurotrophins and their receptor genes following experimental cerebral ischemia in rats — with brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) pathways among those examined. This positions Semax less as a classical receptor agonist and more as a modulator that shifts gene expression toward trophic and survival programs.

Transcriptome-level modulation

Broader transcriptomic analysis published in Genes in 2020 examined ACTH(4-7)PGP effects after cerebral ischaemia-reperfusion in rats, reporting changes across pathways associated with inflammatory and immune response and vascular processes rather than a single narrow target. That study's framing — protective properties observed at the transcriptome level — captures how much of the mechanistic literature is now written: broad expression signatures rather than a lock-and-key receptor story.

Melanocortin receptor interaction

As a melanocortin fragment, interaction with melanocortin receptor subtypes expressed in brain tissue is a reasonable and frequently proposed mechanism. The evidence here is more inferential than definitive, and researchers should treat receptor-level claims about Semax as an open area rather than settled pharmacology.

Metal ion chemistry

A more recent line of investigation treats Semax as a copper-binding peptide. A 2025 paper in Bioinorganic Chemistry and Applications characterized Semax as a copper chelator and reported decreased Cu(II)-catalyzed reactive oxygen species production and reduced cytotoxicity of amyloid-β in that system, attributing the effect to metal ion stripping and redox silencing. The histidine residue in the sequence provides an obvious coordination site. Relatedly, earlier work in Doklady Biological Sciences reported that Semax prevented learning and memory impairment caused by heavy metals in an animal model — a finding that sits comfortably alongside the chelation chemistry.

What the Research Literature Examines

The published body of work on Semax is heavily preclinical, substantially Russian in origin, and organized around a handful of recurring themes. Evidence quality varies considerably by area; the summary below is deliberately hedged.

Cerebral ischemia and neuroprotection

This is the densest area. Rodent models of cerebral ischemia-reperfusion dominate, with endpoints including infarct-related tissue outcomes, neurotrophin and receptor gene transcription, and inflammatory gene expression. Clinical work in Russia has explored ischemic stroke contexts, where the compound has a registered status domestically — but that regulatory history is jurisdiction-specific and does not constitute approval elsewhere. Independent, large-scale, multicenter replication outside that region remains limited.

Cognition, learning, and memory

Rodent behavioral studies report effects on learning acquisition and memory retention, including the heavy-metal-challenge work noted above. A 2020 Doklady Biological Sciences paper applied a functional connectomic approach to studying Selank and Semax effects, examining network-level rather than single-region changes. Human cognitive-performance data are far thinner than the popular discussion suggests, and claims about attention or focus in healthy adults should be read as extrapolation from animal work, not as demonstrated clinical findings.

Neurodegeneration models

A 2025 paper in Acta Naturae assessed the potential of Semax and a derivative for correcting pathological impairments in an animal model of Alzheimer's disease. Combined with the copper-chelation work, this represents an emerging but early-stage direction. Evidence remains preliminary and model-dependent.

Stress physiology and peripheral effects

Work in Bulletin of Experimental Biology and Medicine examined Semax influence on the morphofunctional state of hepatocytes under chronic emotional and painful stress, and a separate paper in the same journal reported anticoagulation and antiplatelet effects under acute and chronic immobilization stress. These peripheral findings are a useful reminder that a peptide studied for central endpoints may show hematological and hepatic signals worth controlling for in study design.

Open topics with weak evidence

Questions circulating in research forums — including whether Semax affects hair growth or hair loss — are not well supported by the peer-reviewed record. Real Peptides maintains a dedicated article examining what the available data actually show on that question.

Laboratory Handling in General Terms

Semax is supplied as a lyophilized (freeze-dried) white powder in sealed vials. General peptide handling principles apply, and the specifics — calculators, step-by-step reconstitution walkthroughs, and error-avoidance guides — live in the child articles rather than here.

• Storage of lyophilized powder: peptides of this class are typically kept refrigerated or frozen, sealed, protected from light, and shielded from atmospheric moisture. Repeated warming and cooling cycles that generate condensation inside a vial are a common and avoidable source of degradation.
• Reconstitution: an appropriate sterile diluent is introduced slowly against the vial wall rather than directed onto the powder cake, and the vial is swirled rather than shaken. Vigorous agitation can shear peptide chains and generate foam.
• Solution stability: once in solution, stability windows are substantially shorter than for dry powder. Solutions are generally kept cold, protected from light, and dated at the point of reconstitution.
• Freeze-thaw: repeated freeze-thaw cycling of reconstituted material is broadly discouraged across peptide chemistry; aliquoting at first reconstitution reduces the problem.
• Documentation: laboratory practice favors recording lot number, diluent identity, reconstitution date, and storage conditions alongside experimental data, so that anomalous results can be traced back to material handling.

Amidated and adamantyl variants may behave differently in solubility and solution stability from base Semax, and should not be assumed interchangeable in handling protocols.

Regulatory and Research-Use Status

Semax is not approved by the FDA for any of the applications discussed on this page. It has not completed the US regulatory pathway for any indication, and it is not a dietary supplement, a food ingredient, or a compounding-eligible substance in the United States. Material supplied by Real Peptides is intended for research use only — in vitro and laboratory investigation by qualified personnel — and is not for human consumption, veterinary use, diagnostic application, or therapeutic purposes of any kind.

Regulatory status differs by jurisdiction. The compound has a domestic registration history in Russia, which is often cited in online discussion but carries no weight in US regulatory terms. Anti-doping status is a separate question governed by the World Anti-Doping Agency's prohibited list and its handling of substances without major regulatory approval; researchers whose work intersects sport science should consult current WADA documentation directly, and Real Peptides maintains a dedicated explainer on that topic. Institutional researchers remain responsible for their own IRB, IACUC, biosafety, and import compliance obligations.

How Researchers Evaluate Supplier Quality

Peptide identity and purity are not visually verifiable. A white powder tells a researcher nothing. The following documentation standards separate credible suppliers from the rest.

A generic COA reused across every batch is a meaningful warning sign, as is a purity figure quoted without a chromatogram behind it. Real Peptides publishes COAs per batch for this reason: a document that cannot be tied to a specific lot cannot support reproducible research. Researchers should also confirm the COA describes the correct chemical entity — an amidated variant will not match the theoretical mass of base Semax, and a mismatch there is either a labeling error or a substitution.

Where the Open Questions Are

Semax is unusual among research peptides in having a long publication history and, simultaneously, large gaps. Several matter for study design.

1. Receptor pharmacology. The primary molecular target or targets are not definitively established. Melanocortin receptor involvement is proposed; direct binding characterization is thinner than the mechanistic narratives suggest.
2. Central nervous system access. How much intact peptide reaches brain tissue, by what route, and in what form is an active question — particularly given that the Pro-Gly-Pro tail is itself bioactive and its cleavage may contribute to observed effects.
3. Geographic concentration of evidence. Much of the foundational literature originates from a small number of research groups. Independent replication in other laboratories would strengthen confidence in the core findings considerably.
4. Human data. Early clinical work reports outcomes in stroke and cognitive contexts, but sample sizes, blinding, and reporting standards vary. Extrapolation to healthy-subject cognition is not supported by the current record.
5. Variant comparability. Whether amidated and adamantyl derivatives share the mechanistic profile of base Semax, or diverge meaningfully, is under-characterized. Most published work concerns the base sequence.
6. Long-duration exposure. Chronic-exposure data — including on the hematological and hepatic parameters flagged in the stress literature — remain limited.

For researchers building a protocol, these gaps are the interesting part. They also define the boundary of what can honestly be said about this compound today: a well-studied peptide with a coherent mechanistic hypothesis, a substantial preclinical record, and a clinical evidence base that has not yet caught up.

Research-grade Semax: Real Peptides supplies Semax for laboratory research with a published third-party Certificate of Analysis for every batch. Research use only.

Explore Semax research on Real Peptides

The articles below go deeper on the questions researchers ask most about Semax.

Reconstitution, storage & handling

• How to Reconstitute Semax Nasal Spray for Reliable Research
• Semax Storage: Does It Really Need to Be Kept Cold? Our Guide
• Does Semax Amidate Need Refrigeration? (Storage Guide)
• How to Reconstitute Semax Amidate? (Step-by-Step)
• Avoid Semax Amidate Reconstitution Errors — Expert Guide

Research questions

• Does Semax Cause Hair Loss? Our Team Investigates the Data
• What Semax Actually Does to Your Brain’s Performance
• Semax Amidate Needles Syringes — Real Peptides

Legal & regulatory

• Is Semax Banned by WADA? The Truth for Athletes & Researchers
• Is Semax Amidate Legal? — Research Use & Regulations
• Is Semax Amidate Legal in 2026? (Current Regulatory Status)
• Semax & FDA Approval: Here’s What You Need to Know

Research timelines & mechanisms

• How Long Semax Amidate Stays in System — Clearance Guide
• How Long Semax Amidate Takes to Work — Onset & Peak Effects
• Semax Amidate Pharmacokinetics — Absorption & Half-Life
• Semax Amidate Nasal Concentration — What Works Best

Stacks & comparisons

• Semax vs Modafinil: Cognitive Enhancer Comparison
• Semax Amidate Stacking Guide — Real Peptides
• Semax vs Adderall — Cognitive Boost Compared | Real Peptides
• Adamax vs Semax Amidate: Research Peptide Comparison
• What Is Semax-Adamantyl Same as Adamax? Key Differences
• What Is N-Adamantyl Semax Same as Adamax? (Explained)

Safety & side effects

• Semax Amidate with Alcohol Safety — What Researchers Know

Buying & quality

• Best Semax Amidate Supplier Third Party Tested 2026
• Semax Amidate Alternatives 2026 Best — Real Peptides
• Buy N-Adamantyl Semax — Research Peptide Guide
• Semax Amidate Reddit Reviews — Real User Experiences

How does Semax differ from Semax Amidate in laboratory research?

Semax is the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, built on the ACTH(4-7) fragment with a C-terminal Pro-Gly-Pro tripeptide added to slow enzymatic breakdown. The amidated analogue replaces the free C-terminal carboxyl group with an amide, a common medicinal-chemistry modification intended to reduce recognition by carboxypeptidases. Researchers comparing the two forms generally focus on relative resistance to proteolysis in plasma or brain homogenate models, and on whether receptor-level activity is preserved after the terminal change. Side-by-side discussions of the free-acid and amidated forms are collected in this comparison of Semax and the amidated analogue, while material-level specifications for a common research presentation appear on the 10 mg amidated Semax page.

The practical research consequence is that the two compounds are not interchangeable reference standards: retention time on reverse-phase HPLC and the molecular ion observed by mass spectrometry both shift slightly with amidation, so an analytical method validated for one form should be re-verified for the other. Discussions of membrane transit and systemic availability of the amidated form are summarized in work on bioavailability characteristics, and handling-related questions are grouped in this research-use and stability FAQ.

What does preclinical animal research on Semax report?

The bulk of published Semax work comes from rodent models, where the peptide has been studied in relation to learning tasks, cerebral ischemia, oxidative stress markers, and neurotrophin expression. Typical experimental designs use maze-based or avoidance-based behavioural endpoints alongside tissue analysis of hippocampal and cortical gene expression. Because Semax originated in Soviet and Russian institutes, a substantial share of this literature was published in Russian-language journals, and English-language abstracts are sometimes the only accessible summary — a factor that complicates meta-analysis and replication. An overview of the animal-model body of work is collected in this survey of what animal research shows.

Researchers reading this literature generally note the gap between rodent findings and controlled human data, a distinction examined directly in this animal versus human research comparison. Injury and neurodegeneration models form two recurring clusters: traumatic and ischemic brain injury paradigms, discussed in work on TBI-related research, and dopaminergic lesion models relevant to Parkinson's-related investigation. Across these clusters, reported mechanisms converge on neurotrophic signalling and inflammatory modulation rather than direct receptor agonism, though attribution remains an open methodological question in many papers.

What does the clinical literature on Semax actually cover?

Semax has been registered in Russia since the 1990s, and much of the clinical literature consists of trials conducted in Russian hospitals examining stroke, optic nerve conditions, and cognitive complaints. These studies vary considerably in size, blinding, and outcome standardization, and most have not been replicated under the trial frameworks used by Western regulators. For that reason, researchers typically treat the clinical record as hypothesis-generating rather than confirmatory, and the practical research question becomes which endpoints could be re-tested under contemporary designs — a theme explored in this overview of trial activity.

Neurodegeneration is a recurring interest area, with discussion of cholinergic and neurotrophic hypotheses collected in work on Alzheimer's-related research. Mood-related endpoints appear less frequently but have been examined through monoamine and BDNF framings, summarized in this review of depression-related research. Importantly, registration in one jurisdiction carries no implication for status elsewhere; Semax holds no approval from the U.S. Food and Drug Administration, and material sold for laboratory work is supplied strictly for in-vitro and preclinical research. That distinction is laid out in detail in this discussion of FDA-approval status.

How do analytical laboratories verify Semax purity and identity?

Two orthogonal methods dominate peptide quality verification. Reverse-phase high-performance liquid chromatography (RP-HPLC), usually on a C18 column with a water/acetonitrile gradient and trifluoroacetic acid modifier, separates the target peptide from truncated sequences, deletion impurities, and residual synthesis reagents; purity is reported as the percentage of total peak area at a fixed UV wavelength, commonly 214 or 220 nm. Mass spectrometry — typically ESI-MS or MALDI-TOF — then confirms identity by matching the observed molecular mass to the theoretical mass of the sequence. Neither method substitutes for the other: HPLC quantifies how much of the sample is one compound, while MS establishes which compound it is.

Supplementary tests may include amino acid analysis, water content by Karl Fischer titration, residual solvent screening, and endotoxin or bioburden testing depending on intended research use. Buyers evaluating documentation can consult this guidance on assessing supplier legitimacy, together with the specification details published for the 10 mg amidated presentation. Questions about how analytical results relate to material behaviour over time are addressed in the stability FAQ and in discussion of degradation after reconstitution.

What should a Semax certificate of analysis contain?

A usable certificate of analysis (COA) is lot-specific and traceable. At minimum it should state the product name and sequence, the lot or batch number, the manufacturing or testing date, the net peptide content, and the purity figure with the method used to generate it. An HPLC chromatogram and a mass spectrum should be reproduced in full rather than summarized as a bare percentage — a standalone number with no trace behind it cannot be independently assessed. The analyzing laboratory should be named, and ideally the COA is issued or confirmed by a third party rather than solely by the seller.

Researchers also watch for internal consistency: the stated molecular weight should match the sequence, the chromatogram axis labels should be legible, and the lot number on the paperwork should match the label on the vial. Documentation practices that distinguish serious suppliers from resellers are outlined in this guide to identifying a legitimate peptide supplier. Because COAs also intersect with compliance obligations, the framework described in this explanation of research-peptide legal rules is relevant, as is the regulatory background summarized under FDA-approval status and the product specification page for 10 mg amidated Semax.

How is lyophilized Semax stored in a research laboratory?

Lyophilized peptide powder is the most stable form of Semax available to laboratories. Freeze-dried material is typically kept sealed, protected from light, and held at low temperature; long-term inventory is commonly stored frozen, while short-term working stock may be refrigerated. The two principal threats to a dry peptide are moisture ingress and repeated temperature cycling. Hygroscopic powder that absorbs atmospheric water can hydrolyse over time, and condensation forming inside a cold vial opened in a warm room is a routine source of avoidable loss, which is why vials are generally allowed to equilibrate to ambient temperature before the seal is broken.

Once a peptide is in solution, its stability profile changes substantially: aqueous Semax is far more susceptible to oxidation at the methionine residue and to enzymatic or chemical cleavage than the dry form. Comparative notes on solution-phase breakdown are collected in this discussion of degradation of reconstituted material, and related handling questions appear in the research-use and stability FAQ. Format and fill-weight considerations for inventory planning are described on the 10 mg amidated Semax page, while absorption-related properties of the amidated form are covered under bioavailability.

What is known about Semax half-life and metabolic fate?

Native ACTH(4-10) is degraded extremely rapidly by peptidases, which is the problem the Pro-Gly-Pro extension was designed to address. The terminal proline-containing tripeptide hinders exopeptidase attack, and the resulting Semax molecule persists measurably longer in biological fluids than the parent fragment, though it remains a short-lived peptide by pharmacological standards. Amidation of the C-terminus is a further modification aimed at the same goal. Degradation in model systems proceeds largely through sequential cleavage from the termini, generating shorter fragments — some of which, including Pro-Gly-Pro itself, have been studied independently for biological activity.

This short persistence creates an interpretive challenge: reported effects in neurotrophin expression and behavioural models frequently outlast the measurable presence of the intact peptide, which suggests the compound acts as a trigger for downstream transcriptional events rather than through sustained receptor occupancy. That reasoning is developed further in this examination of downstream effects and in work on the gene-expression mechanism. Related material on membrane transit and systemic uptake is collected under bioavailability, while in-solution breakdown relevant to bench timing is discussed in degradation of reconstituted material.

Why is Semax studied in connection with BDNF and NGF?

Neurotrophin induction is the most frequently cited mechanistic hypothesis for Semax. Published rodent work has examined hippocampal expression of brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and their cognate receptors TrkB and TrkA following peptide exposure, generally reporting changes in transcript and protein levels rather than direct binding of the peptide to those receptors. The proposed sequence is indirect: Semax influences intracellular signalling cascades that converge on transcription factors regulating neurotrophin genes, and the resulting BDNF/TrkB activity then drives the synaptic and plasticity-related changes observed downstream.

This framing matters because it predicts delayed and cumulative effects rather than immediate ones, and it makes transcriptional endpoints more informative than acute behavioural readouts in short experiments. Detailed treatment of the signalling pathway is available in this account of how the BDNF mechanism works and in this review of BDNF and NGF upregulation research. The transcriptional layer — including reported effects on genes associated with inflammation and vascular response — is covered in work on gene expression, and the behavioural consequence most often paired with neurotrophin endpoints is examined in learning-related research.

Why does Semax appear in attention and focus research models?

Attention-related endpoints recur in the Semax literature partly because of the peptide's melanocortin ancestry. ACTH-derived fragments have long been investigated for behavioural effects on arousal, attention, and memory consolidation independent of corticosteroid release, and Semax was developed within that research tradition. Modern work extends the question to monoamine systems, examining whether the peptide modulates dopaminergic and serotonergic tone in cortical and striatal regions, which would offer a plausible route to attention-relevant effects. That line of investigation is summarized in work on dopamine and serotonin modulation.

Preclinical attention paradigms used in this area include sustained-response tasks, impulsivity measures, and novelty-driven exploration, each probing a different component of what "attention" means operationally. Because the construct is multidimensional, apparently conflicting results across studies often reflect different task demands rather than genuine contradiction. Background on these framings is collected in this overview of focus and attention research and in a mechanism-focused discussion of attention pathways. Investigators approaching the topic from a disorder-model angle may find the methodological considerations in this ADHD research mechanism review useful for understanding how translational claims in this area should be weighed.

References

Peer-reviewed sources on Semax indexed in PubMed, listed for research context. Real Peptides supplies Semax for laboratory research use only.

1. The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease. Acta naturae, 2025. PMID 41479572. doi:10.32607/actanaturae.27808
2. Semax, a Copper Chelator Peptide, Decreases the Cu(II)-Catalyzed ROS Production and Cytotoxicity of aβ by Metal Ion Stripping and Redox Silencing. Bioinorganic chemistry and applications, 2025. PMID 40496623. doi:10.1155/bca/4226220
3. Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2020. PMID 32342318. doi:10.1134/S001249662001007X
4. Novel Insights into the Protective Properties of ACTH((4-7))PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats. Genes, 2020. PMID 32580520. doi:10.3390/genes11060681
5. Influence of ACTG(4-7)-PGP (Semax) on Morphofunctional State of Hepatocytes in Chronic Emotional and Painful Stress. Bulletin of experimental biology and medicine, 2017. PMID 28577097. doi:10.1007/s10517-017-3748-4
6. Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2017. PMID 28702721. doi:10.1134/S0012496617030048
7. Semax prevents learning and memory inhibition by heavy metals. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 2016. PMID 27411820. doi:10.1134/S0012496616030066
8. The effect of Semax and its C-end peptide PGP on the morphology and proliferative activity of rat brain cells during experimental ischemia: a pilot study. Journal of molecular neuroscience : MN, 2011. PMID 20617398. doi:10.1007/s12031-010-9421-2